Mergers and innovation in big pharma

International Journal of Industrial Organization

Volumn 27, Issue 1, 2009, Pages 70-79

  Ornaghi, Carmine ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Innovation; M A; Product relatedness; Technological relatedness

Indexed keywords

DRUG PRODUCTS PLANTS; MERGERS AND ACQUISITIONS;

BIG PHARMA; CONTROL GROUPS; EMPIRICAL RESULTS; PHARMACEUTICAL INDUSTRIES; PRODUCT RELATEDNESS; PROPENSITY SCORES; TECHNOLOGICAL RELATEDNESS; WORSE PERFORMANCES;

MERGING;

EID: 58149161992     PISSN: 01677187     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijindorg.2008.04.003     Document Type: Article

References (20)

1. Andrade G., Mitchell M., and Stafford E. New evidence and perspectives on mergers. Journal of Economic Perspectives 15 (2001) 103-120
2. Bertrand, O., Zitouna, H., in press. Domestic vs. Cross-border Acquisitions: which impact on the Target Firms Performance? lied Economics. doi:10.1080/00036840600949397
3. Bloom N., Schankerman M., and Van Reenen J. Identifying technology spillovers and product market rivalry. CEP discussion paper No.0675 (2005)
4. Blundell R., and Costa Dias M. Evaluation methods for non-experimental data. Fiscal Studies 21 4 (2000) 427-468
5. Cassiman B., Colombo M., Garrone P., and Veugelers R. The impact of M&A on the R&D process. Research Policy 34 2 (2005) 195-220
6. Danzon P.M., Epstein A., and Nicholson S. Mergers and acquisitions in the pharmaceutical and biotech industries. NBER Working Paper N. 10536 (2004)
7. Danzon P.M., Nicholson S., and Pereira N.S. Productivity in pharmaceutical-biotechnology R&D: the role of experience and alliances. NBER Working Paper N. 9615 (2003)
8. Dehejia R.H., and Wahba S. Propensity score-matching methods for nonexperimental causal studies. Review of Economics and Statistics 84 1 (2002) 151-161
9. Hall B. The effects of takeover activity on corporate research and development. NBER Working Paper N. 2191 (1987)
10. Henderson R., and Cockburn I. Scale, scope and spillovers: determinants of research productivity in drug discovery. Rand Journal of Economics 27 (1996) 32-59
11. Jaffe A.B. Technological opportunity and spillovers of R&D: evidence from firms' patents, profits, and market value. American Economic Review 76 (1986) 984-1001
12. Kamien M.I., Muller E., and Zang I. Research joint ventures and R&D cartels. American Economic Review 82 (1992) 1293-1306
13. Katz M.L., and Shelanski H.A. Merger policy and innovation: must enforcement change to account for technological change?. NBER Working Paper N. 10710 (2004)
14. Marco, A.C. and Rausser, G.C. (2002), "Complementarities and Spill-overs in Mergers: An Empirical Investigation Using Patent Data". mimeo.
15. Mueller D.C. Lessons from the United States' antitrust history. International Journal of Industrial Organization 14 (1996) 415-445
16. Ravenscraft D.J., and Long W.F. Paths to creating value in pharmaceutical mergers. In: Kaplan S.N. (Ed). Mergers and Productivity (2000), University of Chicago Press, Chicago
17. Rosenbaum P., and Rubin D.B. The central role of the propensity score in observational studies for causal effects. Biometrika 70 1 (1983) 41-55
18. Scherer F.M. The pharmaceutical industry - prices and progress. The New England Journal of Medicine 351 (2004) 927-932
19. Trajtenberg M., Jaffe A.B., and Hall B.H. The NBER patent citation data file: lessons, insight and methodological tools. NBER Working Paper N. 8498 (2001)
20. White J.L. Antitrust and merger policy: a review and critique. Journal of Economic Perspectives 1 (1987) 13-22